+44.3%
AXON vs MRNA
+221.0%
-176.7%
-65.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.7% | -3.4% | +6.2% | +2.8% |
| 7D | +0.8% | -12.1% | +12.9% | +1.3% |
| 30D | -22.8% | -1.3% | -21.5% | -22.9% |
| 3M | -48.8% | +250.9% | -299.7% | -52.8% |
| 6M | -16.3% | +343.0% | -359.3% | -24.0% |
| YTD | -44.5% | +657.4% | -701.9% | -51.0% |
| 1Y | -43.4% | +794.9% | -838.3% | -50.3% |
| 3Y | +44.3% | +218.1% | -173.9% | +25.0% |
| All | +44.3% | +221.0% | -176.7% | +25.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling